83 related articles for article (PubMed ID: 22760210)
1. Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
Esposito A; Munzone E; Bagnardi V; Adamoli L; Sciandivasci A; Cullurà D; Goldhirsch A; Nolè F
Anticancer Drugs; 2012 Nov; 23(10):1089-98. PubMed ID: 22760210
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
Nishimura R; Okumura Y; Arima N
Breast Cancer; 2008; 15(1):57-64. PubMed ID: 18224396
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.
García-Sáenz JA; Martín M; Puente J; López-Tarruella S; Casado A; Moreno F; Grande E; Díaz-Rubio E
Clin Breast Cancer; 2005 Oct; 6(4):325-9. PubMed ID: 16277882
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.
Montemurro F; Donadio M; Clavarezza M; Redana S; Jacomuzzi ME; Valabrega G; Danese S; Vietti-Ramus G; Durando A; Venturini M; Aglietta M
Oncologist; 2006 Apr; 11(4):318-24. PubMed ID: 16614227
[TBL] [Abstract][Full Text] [Related]
5. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
Stemmler HJ; Kahlert S; Siekiera W; Untch M; Heinrich B; Heinemann V
Onkologie; 2005 Nov; 28(11):582-6. PubMed ID: 16249644
[TBL] [Abstract][Full Text] [Related]
6. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study.
Campiglio M; Bufalino R; Sandri M; Ferri E; Aiello RA; De Matteis A; Mottolese M; De Placido S; Querzoli P; Jirillo A; Bottini A; Fantini M; Bonetti A; Pedani F; Mauri M; Molino A; Ferro A; Pupa SM; Sasso M; Ménard S; Balsari A; Tagliabue E
Breast Cancer Res Treat; 2011 Jul; 128(1):147-54. PubMed ID: 21479926
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab treatment in multiple lines: current data and future directions.
Pegram M; Liao J
Clin Breast Cancer; 2012 Feb; 12(1):10-8. PubMed ID: 22154153
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
11. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
[TBL] [Abstract][Full Text] [Related]
12. Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.
Metro G; Giannarelli D; Gemma D; Lanzetta G; Ciccarese M; Papaldo P; Gamucci T; Lorusso V; Mottolese M; Magnolfi E; Cognetti F; Fabi A
Breast J; 2010; 16(1):66-72. PubMed ID: 19889170
[TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
Santini D; Vincenzi B; Adamo V; Addeo R; Fusco V; Russo A; Montemurro F; Roato I; Redana S; Lanzetta G; Satolli MA; Berruti A; Leoni V; Galluzzo S; Antimi M; Ferraro G; Rossi M; Del Prete S; Valerio MR; Marra M; Caraglia M; Tonini G
Oncol Rep; 2011 Jun; 25(6):1545-8. PubMed ID: 21455582
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
15. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
16. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
19. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
Ruiz M; Salvador J; Bayo J; Lomas M; Moreno A; Valero M; Bernabé R; Vicente D; Jiménez J; Lopez-Ladrón A
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1085-90. PubMed ID: 18365200
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]